CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma
April 20th 2018Owen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL). This can be tricky for a number of reasons, but O’Connor is hopeful that there are treatment regimens for this patient population that can work.
Watch
Co-Clinical Trial of Olaparib and Temozolomide in SCLC PDX Models
April 18th 2018Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.
Watch
Examining Self-Reported Symptoms in Patients With Multiple Myeloma
April 18th 2018Joshua R. Richter, MD, a hematologist/oncologist at John Theurer Cancer Center, discusses results from the Living with Cancer patient-reported outcomes (PROs) tool, which is a survey to record self-reported symptoms from patients. Richter used this tool to survey 239 patients with multiple myeloma on their symptoms and psychological distress.
Watch
Challenges With Triplet Regimens for the Treatment of Hematologic Malignancies
April 18th 2018Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events.
Watch
Findings With the Antibody Drug Conjugate D3-GPC2-PBD
April 18th 2018Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
Watch
Results of Pembrolizumab in High-Risk Stage III Melanoma
April 17th 2018Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the phase III results from the EORTC 1325-MG/KEYNOTE-054 trial presented at the 2018 AACR Annual Meeting.
Watch
Targeting RET Alterations With Selective Inhibitor BLU-667
April 16th 2018Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses targeting <em>RET </em>alterations in solid tumors during the 2018 AACR Annual Meeting.
Watch
Selecting Patients for Treatment With Ibrutinib in CLL
April 14th 2018Jacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia are the best candidates for treatment with ibrutinib
Watch